Autotaxin Identified as Glaucoma Fibrosis Driver
Researchers found that targeting the autotaxin pathway reduces fibrotic gene expression in human glaucoma cells.
Updated on Oct. 11, 2026 in Biotech
Live Poll
Does new research on enzyme inhibitors increase your confidence in future treatments for glaucoma?
Researchers have identified autotaxin and its receptors as key contributors to the fibrosis observed in glaucoma-affected lamina cribrosa cells. This research-stage finding demonstrates that inhibiting this pathway can reduce the expression of genes involved in scar tissue formation.
Why it matters
Understanding this molecular driver could open a path to slowing or preventing the structural damage in the eye that characterizes progressive glaucoma. This study provides a new cellular target for potential therapies aimed at modifying the disease course.
Glaucoma cells showed a 2.73-fold increase in LPA receptor expression compared to controls. Treatment with the inhibitor S32826 reduced COL1A gene expression to 0.51 of baseline and FN1 expression to 0.64 of baseline.
The details
Researchers used RT-qPCR—a method for quantifying RNA levels—alongside western blotting to confirm elevated autotaxin levels in lamina cribrosa cells, the microscopic tissue in the eye that can become rigid in glaucoma. They then utilized S32826, a chemical inhibitor that blocks the activity of the autotaxin enzyme, to assess changes in cell behavior. The treatment effectively suppressed the expression of collagen (COL1A) and fibronectin (FN1), which are primary proteins involved in the formation of fibrotic scar tissue.
Timeline
The research findings were published on October 11, 2026.
The Tech Race
This work advances the ongoing investigation into lamina cribrosa fibrosis in glaucoma by identifying a specific enzyme mediator. It establishes a new potential therapeutic target that contrasts with existing treatments focused primarily on intraocular pressure reduction.
This finding does not immediately change patient care, as the work is currently limited to cellular-level research. Future studies must now determine if these laboratory-demonstrated reductions in fibrotic gene expression can be replicated in clinical models or pharmacological trials.
The takeaway
This discovery highlights the autotaxin pathway as a critical site for potential glaucoma interventions. Observers should monitor future studies for the development of systemic or topical inhibitors that can safely demonstrate reduced fibrosis in animal models.
Further reading
Explore more developments in eye disease research at Biotech.
Source note: This article includes information reported by Nature.
Live Poll
Does new research on enzyme inhibitors increase your confidence in future treatments for glaucoma?
